Final common pathways of progression of renal diseases

Clinical and Experimental Nephrology

Volumn 6, Issue 4, 2002, Pages 182-189

  Nangaku, Masaomi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Complement; Ischemia; Tubulointerstitial damage

Indexed keywords

CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; COLLAGEN; COMPLEMENT; COMPLEMENT MEMBRANE ATTACK COMPLEX; GELATINASE A; GELATINASE B; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; LAMININ; MONOCYTE CHEMOTACTIC PROTEIN 1; PROSTAGLANDIN E2; REACTIVE OXYGEN METABOLITE; SELECTIN; THROMBOXANE A2; TUMOR NECROSIS FACTOR;

COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; DISEASE COURSE; GLOMERULONEPHRITIS; HUMAN; IMMUNOPATHOGENESIS; IMMUNOREGULATION; KIDNEY DISEASE; KIDNEY FAILURE; PATHOPHYSIOLOGY; PROTEINURIA; REVIEW;

EID: 0036962611     PISSN: 13421751     EISSN: None     Source Type: Journal    
DOI: 10.1007/s101570200032     Document Type: Review

References (66)

1. Couser WG. Molecular mechanisms of experimental glomerulonephritis: an overview. Nephrology 1997;3:S633-7.
2. Brandt J, Pippin J, Schulze M, Hansch GM, Alpers CE, Johnson RJ, et al. Role of the complement membrane attack complex (C5b-9) in mediating experimental mesangioproliferative glomerulonephritis. Kidney Int 1996;49:335-43.
3. Nangaku M, Alpers CE, Pippin J, Shankland SJ, Adler S, Kurokawa K, et al. Renal microvascular injury induced by antibody to glomerular endothelial cells is mediated by C5b-9. Kidney Int 1997;52:1570-8.
4. Shao J, Miyata T, Yamada K, Hanafusa N, Wada T, Gordon KL, et al. A protective role of nitric oxide in a model of thrombotic microangiopathy in rats. J Am Soc Nephrol 2001;12:2088-97.
5. Hughes J, Nangaku M, Alpers CE, Shankland SJ, Couser WG, Johnson RJ. The C5b-9 membrane attack complex mediates endothelial cell apoptosis in experimental glomerulonephritis. Am J Physiol 2000;278:F747-57.
6. Nangaku M. Complement regulatory proteins in glomerulonephritis. Kidney Int 1998;54:1419-28.
7. Nangaku M, Johnson RJ, Couser WG. Complement regulatory proteins and glomerulonephritis. Exp Nephrol 1997;5:345-54.
8. Hanafusa N, Sogabe H, Yamada K, Wada T, Fujita T, Nangaku M. Contribution of genetically engineered animals to the analyses of complement in the pathogenesis of nephritis. Nephrol Dial Transplant (in press).
9. Sogabe H, Nangaku M, Ishibashi Y, Wada T, Fujita T, Sun X, et al. Increased susceptibility of decay-accelerating factor (DAF) deficient mice to anti-GBM glomerulonephritis. J Immunol 2001;167:2791-7.
10. Nangaku M, Alpers CE, et al. CD59 protects glomerular endothelial cells from immune mediated thrombotic microangiopathy in rats. J Am Soc Nephrol 1998;9:590-7.
11. Matsuo S, Nishikage H, Yoshida F, Nomura A, Piddlesden SJ, Morgan BP. Role of CD59 in experimental glomerulonephritis in rats. Kidney Int 1994;46:191-200.
12. Cosio F, Shibata T, Rovin BH, Birmingham DJ. Effects of complement activation products on the synthesis of decay accelerating factor and membrane cofactor protein by human mesangial cells. Kidney Int 1994;46:986-92.
13. Shibata T, Kohsaka T. Effects of complement activation on the expression of CD59 by human mesangial cells. J Immunol 1995;155:403-9.
14. Moutabarrik A, Nakanishi I, Matsumoto M, Zaid D, Seya T. Human glomerular epithelial cells synthesize and secrete the third component of complement. Nephron 1995;70:55-61.
15. Shibata T, Cosio FG, Birmingham DJ. Complement activation induces the expression of decay-accelerating factor on human mesangial cells. J Immunol 1991;147:3901-8.
16. Yamada K, Hori Y, Hanafusa N, Okuda T, Nanago N, Choi-Miura N-H, et al. Clusterin is up-regulated in glomerular mesangial cells in complement-mediated injury. Kidney Int 2001;59:137-46.
17. Saunders J, Aminian A, McRae JL, O'Farrell KA, Adam WR, Murphy BF. Clusterin depletion enhances immune glomerular injury in the isolated perfused kidney. Kidney Int 1994;45:817-27.
18. Noris M, Remuzzi G. Familial and recurrent forms of hemolytic uremic syndrome/thrombotic thrombocytopenic purpura. Contrib Nephrol 2001;136:125-39.
19. Zipfel P. Hemolytic uremic syndrome: how do factor H mutants mediate endothelial damage? Trends Immunol 2001;22:345-8.
20. Brenner BM, Lawler EV, Mackenzie HS. The hyperfiltration theory: a paradigm shift in nephrology. Kidney Int 1996;49:1774-7.
21. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 1994;330:877-84.
22. Macconi D, Ghilardi M, Bonassi ME, Mohamed EI, Abbate M, Colombi F, et al. Effect of angiotensin-converting enzyme inhibition on glomerular basement membrane permeability and distribution of zonula occludens-1 in MWF rats. J Am Soc Nephrol 2000;11:477-89.
23. Benigni A, Tomasoni S, Gagliardini E, Zoja C, Grunkemeyer JA, Kalluri R, Remuzzi G. Blocking angiotensin II synthesis/activity preserves glomerular nephrin in rats with severe nephrosis. J Am Soc Nephrol 2001;12:941-8.
24. Ruggenenti P, Mosconi L, Vendramin G, Moriggi M, Remuzzi A, Sangalli F, et al. ACE inhibition improves glomerular size selectivity in patients with idiopathic membranous nephropathy and persistent nephrotic syndrome, Am J Kidney Dis 2000;35:381-91.
25. Remuzzi A, Perico N, Sangalli F, Vendramin G, Moriggi M, Ruggenenti P, et al. ACE inhibition and ANG II receptor block-ade improve glomerular size-selectivity in IgA nephropathy. Am J Phvsiol 1999;276:F457-66.
26. Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppor Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril efficacy in nephropathy. Lancet 1998;352:1252-6.
27. Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP, et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 2001;285:2719-28.
28. Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001;135:73-87.
29. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, Marcantoni C, et al. Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int 2001;60:1131-40.
30. Ruggenenti P, Remuzzi G. The role of protein traffic in the progression of renal diseases, Annu Rev Med 2000;51:315-27.
31. Brunskill NJ, Mechanisms of albumin uptake by proximal tubular cells. Am J Kidney Dis 2001;37(1 Suppl 2):S17-20.
32. Remuzzi G, Ruggenenti P, Perico N. Chronic renal diseases: renoprotective benefits of renin-angiotensin system inhibition. Ann Intern Med 2002;136:604-15.
33. Morita Y, Nomura A, Yuzawa Y, Nishikawa K, Hotta N, Shimizu F, et al. The role of complement in the pathogenesis of tubulointerstitial lesions in rat mesangial proliferative glomerulonephritis. J Am Soc Nephrol 1997;8:1363-72.
34. Nomura A, Morita Y, Maruyama S, Hotta N, Nadai M, Wang L, et al. Role of complement in acute tubulointerstitial injury of rats with aminonucleoside nephrosis. Am J Pathol 1997;151:539-47.
35. Morita Y, Ikeguchi H. Nakamura J, Hotta N, Yuzawa Y, Matsuo S. Complement activation products in the urine from proteinuric patients. J Am Soc Nephrol 2000;11:700-7.
36. Nangaku M, Pippin J, Couser WG. Complement membrane attack complex (C5b-9) mediates interstitial disease in experimental nephrotic syndrome. J Am Soc Nephrol 1999;10:2323-31.
37. Abbate M, Zoja C, Corna D, Capitanio M, Bertani T, Remuzzi G. In progressive nephropathies, overload of tubular cells with filtered proteins translates glomerular permeability dysfunction into cellular signals of interstitial inflammation. J Am Soc Nephrol 1998;9:1213-24.
38. Abbate M, Zoja C, Rottoli D, Corna D, Perico N, Bertani T, et al. Antiproteinuric therapy while preventing the abnormal protein traffic in proximal tubule abrogates protein- and complement-dependent interstitial inflammation in experimental renal disease. J Am Soc Nephrol 1999;10:804-13.
39. Nangaku M, Pippin J, Couser WG. C6 mediates chronic progression of tubulointerstitial damage in remnant kidney rats. J Am Soc Nephrol 2002;13:928-36.
40. Hori Y, Yamada K, Hanafusa N, Okuda T, Okada N, Miyata T, et al. Crry, a complement regulatory protein, modulates renal interstitial disease induced by proteinuiria. Kidney Int 1999;56:2096-106.
41. Couser WG, Johnson RJ, Young BA, Yeh G, Toth CA, Rudolph AR. The effects of soluble recombinant complement receptor 1 on complement-mediated experimental glomerulonephritis. J Am Soc Nephrol 1995;5:1888-94.
42. Quigg RJ, He C, Lim A, Berthiaume D, Alexander JJ, Kraus D, et al. Transgenic mice overexpressing the complement inhibitor Crry as a soluble protein are protected from antibody-induced glomerular injury. J Exp Med 1998;188:1321-31.
43. Quigg RJ, Kozono Y, Berthiaume D, Lim A, Salant DJ, Weinfeld A, et al. Blockade of antibody-induced glomerulonephritis with Crry-Ig, a soluble murine complement inhibitor. J Immunol 1998;160:4553-60.
44. Bao L, Haas M, Boackle SA, Kraus DM, Cunningham PN, Park P, et al. Transgenic expression of a soluble complement inhibitor protects against renal disease and promotes survival in MRL/1pr mice. J Immunol 2002;168:3601-7.
45. Nangaku M, Meek RL, Pippin J, Gordon KL, Morgan BP, Johnson RJ, et al. Transfected CD59 protects mesangial cells from injury induced by antibody and complement. Kidney Int 1996;50:257-66.
46. Nangaku M, Quigg RJ, Shankland ST, Okada N, Johnson RJ, Couser WG. Overexpression of Crry protects mesangial cells from complement mediated injury. J Am Soc Nephrol 1997;8:223-33.
47. Wang Y, Hu Q, Madri JA, Rollins SA, Chodera A, Matis LA. Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. Proc Natl Acad Sci USA 1996;93:8563-8.
48. Fung M, Loubser PG, Undar A, Mueller M, Sun C, Sun WN, et al. Inhibition of complement, neutrophil, and platelet activation by an anti-factor D monoclonal antibody in simulated cardiopulmonary bypass circuits. J Thorac Cardiovasc Surg 2001;122:113-22.
49. Sahu A, Soulika AM, Morikis D, Spruce L, Moore WT, Lambris JD. Binding kinetics, structure-activity relationship, and biotransformation of the complement inhibitor compstatin. J Immunol 2000;615:2491-9.
50. Biesecker G, Dihel L, Enney K, Bendele RA. Derivation of RNA aptamer inhibitors of human complement C5. Immunopharmacology 1999;42:219-30.
51. Grant E, Guiadeen D, Singer M, Argentieri D, Hlasta DJ, Wachter M. Design, synthesis, and biological activity of diiminoisoindolines as complement component 3a antagonists. Bioorg Med Chem Lett 2001;11:2817-20.
52. Fine LG, Bandyopadhay D, Norman JT. Is there a common mechanism for the progression of different types of renal diseases other than proteinuria? Towards the unifying theme of chronic hypoxia. Kidney Int 2000;75:S22-6.
53. Kang DH, Kanellis J, Hugo C, Truong L, Anderson S, Kerjaschki D, et al. Role of the microvascular endothelium in progressive renal disease. J Am Soc Nephrol 2002;13:806-16.
54. Ohashi R, Kitamura H, Yamanaka N. Peritubular capillary injury during the progresion of experimental glomerulonephritis in rats. J Am Soc Nephrol 2000;11:47-56.
55. Nangaku M, Yamada K, Gariepy CE, Miyata T, Inagi R, Kurokawa K, et al. ETB receptor protects the tubulointerstitium in experimental thrombotic microangiopathy. Kidney Int (in press).
56. Kang DH, Joly AH, Oh SW, Hugo C, Kerjaschki D, Gordon KL. et al. Impaired angiogenesis in the remnant kidney model: I. Potential role of vascular endothelial growth factor and thrombospondin-1. J Am Soc Nephrol 2001;12:1434-47.
57. Kang DH, Hughes J, Mazzali M, Schreiner GF, Johnson RJ. Impaired angiogenesis in the remnant kidney model: II. Vascular endothelial growth factor administration reduces renal fibrosis and stabilizes renal function. J Am Soc Nephrol 2001;2:1448-57.
58. Suga S, Kim YG, Joly A, Puchacz E, Kang DH, Jefferson JA, et al. Vascular endothelial growth factor (VEGF121) protects rats from renal infarction in thrombotic microangiopathy. Kidney Int 2001;60:1297-308.
59. Kim YG, Suga SI, Kang DH, Jefferson JA, Mazzali M, Gordon KL, et al. Vascular endothelial growth factor accelerates renal recovery in experimental thrombotic microangiopathy. Kidney Int 2000;58:2390-99.
60. Bohle A, Mackensen-Haen S, Wehrmann M. Significance of post-glomerular capillaries in the pathogenesis of chronic renal failure. Kidney Blood Press Res 1996;19:191-5.
61. Choi YJ, Chakraborty S, Nguyen V, Nguyen C, Kim BK, Shim SI, et al. Peritubular capillary loss is associated with chronic tubulointerstitial injury in human kidney: altered expression of vascular endothelial growth factor. Human Pathol 2000;31:1491-7.
62. Zeisberg M, Strutz F, Muller GA. Role of fibroblast activation in inducing interstitial fibrosis. J Nephrol 2000;13(suppl 3):S111-20.
63. Norman JT, Clark IM, Garcia PL. Hyopxia promotes fibrogenesis in human renal fibroblasts. Kidney Int 2000;58:2351-66.
64. Norman JT, Orphanides C, Garcia P, Fine LG. Hypoxia-induced changes in extracellular matrix metabolism in renal cells. Exp Nephrol 1999;7:463-9.
65. Weinberg JM, Venkatachalam MA, Roeser NF, Nissim I. Mitochondrial dysfunction during hypoxia/reoxygenation and its correction by anaerobic metabolism of citric acid cycle intermediates. Proc Natl Acad Sci USA 2000;97:2826-31.
66. Khan S, Cleveland RP, Koch CJ, Schelling JR. Hypoxia induces renal tubular epithelial cell apoptosis in chronic renal disease. Lab Invest 1999;79:1089-99.